Impact of Baseline Clinicopathologic and Genomic Features on Outcomes to KRAS G12C Inhibitors in Patients with NSCLC

被引：0
|
作者：
Lamberti, G. [1 ]
Ricciuti, B. [1 ]
Alessi, J. V. [1 ]
Barrichello, A. P. C. [1 ]
Pecci, F. [1 ]
Vaz, V. R. [1 ]
Sholl, L. M. [2 ]
Awad, M. M. [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] Brigham & Womens Hosp, Boston, MA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
KRAS G12C; KRAS inhibitors; Predictive factors;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA02.09
引用
收藏
页码：S49 / S49
页数：1
相关论文
共 50 条
  • [1] Impact of baseline clinicopathologic and genomic features on outcomes to KRAS G12C inhibitors in patients with NSCLC
    Lamberti, G.
    Cooper, A. J.
    Ricciuti, B.
    Alessi, J. V.
    Barrichello, A. P. de Castro
    Pecci, F.
    Vaz, V. R.
    Nishino, M.
    Sholl, L. M.
    Heist, R.
    Awad, M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1039 - S1039
  • [2] Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC
    Brazel, Danielle
    Nagasaka, Misako
    TARGETED ONCOLOGY, 2024, 19 (03) : 297 - 301
  • [3] Toxicities Associated with Immune Checkpoint Inhibitors Followed by KRAS G12C Inhibitors in Patients with Metastatic NSCLC
    Kagalwalla, S.
    Patel, M.
    Fujioka, N.
    Manning, B.
    Kratzke, R.
    Kulkarni, A. A.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S648 - S649
  • [4] KRAS G12C mutations in Hispanic and non-Hispanic patients with NSCLC: clinicopathologic characteristics and prognosis
    Manoharan, Aysswarya
    Kareff, Samuel A.
    Ramos, Leana M.
    El-Abbar, Nora A.
    Lopes, Gilberto
    Rodriguez, Estelamari
    CANCER RESEARCH, 2023, 83 (07)
  • [5] Targeting KRAS G12C with Covalent Inhibitors
    Ostrem, Jonathan M. L.
    Shokat, Kevan M.
    ANNUAL REVIEW OF CANCER BIOLOGY, 2022, 6 : 49 - 64
  • [6] Mechanisms of Resistance to KRAS G12C Inhibitors
    Ambrogio, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S96 - S96
  • [7] The promise and peril of KRAS G12C inhibitors
    Moore, Amanda R.
    Malek, Shiva
    CANCER CELL, 2021, 39 (08) : 1059 - 1061
  • [8] Clinical Data for KRAS G12C Inhibitors
    Kim, H. R.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S95 - S96
  • [9] EMT is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C mutant NSCLC
    Adachi, Yuta
    Ito, Kentaro
    Kimura, Ryo
    Yamaguchi, Rui
    Ebi, Hiromichi
    ANNALS OF ONCOLOGY, 2021, 32 : S307 - S307
  • [10] Distant Metastasis Pattern and Baseline Clinicopathological Features from a Real-World KRAS G12C Mutant Cohort of Advanced NSCLC Patients
    Mollica, L.
    Intagliata, S.
    Bonomi, L.
    Ghilardi, L.
    Morotti, D.
    Ghirardi, G.
    Antelmi, E.
    Gianatti, A.
    Carioli, G.
    Muglia, R.
    Marra, P.
    Raimondi, F.
    Ciaravino, G.
    Di Marco, F.
    Sironi, S.
    Tondini, C. A.
    Bettini, A. C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S495 - S496
12345